Research Article: Mitigating effect of tanshinone IIA on ventricular remodeling in rats with pressure overload-induced heart failure 1

Date Published: October 14, 2019

Publisher: Sociedade Brasileira para o Desenvolvimento da Pesquisa em Cirurgia

Author(s): Xu Li, Daokang Xiang, Yizhu Shu, Xiangjun Zeng, Yonghong Li.

http://doi.org/10.1590/s0102-865020190080000007

Abstract

To investigate the effect of tanshinone IIA (TIIA) on ventricular remodeling in rats with pressure overload-induced heart failure.

Pressure overload-induced heart failure model (abdominal aortic coarctation) was established in 40 rats, which were divided into model and 5, 10 and 20 mg/kg TIIA groups. Ten rats receiving laparotomy excepting abdominal aortic coarctation were enrolled in sham-operated group. The 5, 10 and 20 mg/kg TIIA groups were treated with 5, 10 and 20 mg/kg TIIA, respectively, for 8 weeks.

Compared with model group, in 20 mg/kg TIIA group the left ventricular ejection fraction, left ventricular fractional shortening, left ventricular systolic pressure, ±maximum left ventricular pressure rising and dropping rate, and myocardial B-cell lymphoma-2 and cleaved cysteinyl aspartate specific proteinase-3 protein levels were increased, respectively (P<0.05), and the left ventricular end diastolic diameter, left ventricular end systolic diameter, left ventricular end diastolic pressure, heart weight index, left ventricular weight index, serum B-type brain natriuretic peptide, interleukin 6 and C-reactive protein levels and myocardial B-cell lymphoma-2 associated X protein level were decreased, respectively (P<0.05). TIIA may alleviate ventricular remodeling in rats with pressure overload-induced heart failure heart by reducing inflammatory response and cardiomyocyte apoptosis.

Partial Text

Heart failure refers to the syndrome presented by circulatory system dysfunction due to absolute or relative insufficiency of cardiac output under sufficient venous blood reflux. Heart failure is the last common pathway of various cardiovascular diseases, and has increasingly become a major public health problem threatening the human health 1 . The treatment of heart failure is progressing with the deepening of understanding of its pathophysiological mechanism. It has been recognized that the ventricular remodeling is the basic mechanism for the occurrence and development of heart failure 2 . Ventricular remodeling refers the changes in cardiac structure, function and phenotype due to a series of complex cellular and molecular mechanisms, including cardiomyocyte hypertrophy, apoptosis, re-expression of embryonic genes and proteins, and changes in extracellular matrix 3 – 5 . There are many methods to treat heart failure nowadays. The common used drugs often have some toxic and side effects. In addition, the new treatment methods such as stem cell therapy, pacing therapy, heart transplantation and application of ventricular assist devices are rarely clinically used, expensive, and difficult to be accepted by the common people 6 – 9 . Salvia miltiorrhiza Bge. is a popular medicinal herb. Modern medicine has proved that Salvia miltiorrhiza Bge. can remove the impurities in blood, promote the activity of fibrinolytic enzyme, reduce the blood viscosity, promote thrombolysis, smooth the blood vessels and protect the cardiovascular system 10 . Tanshinone IIA (TIIA) is the main active ingredient of Salvia miltiorrhiza Bge. TIIA has many biological activities, especially in resisting oxidant stress and reducing inflammatory response aspects 11 , 12 . In addition, TIIA has a protective effect on myocardial ischemia 13 . Therefore, it is speculated that TIIA may also have protective effects on ventricular remodeling in heart failure. This study investigated the mitigating effect of TIIA on ventricular remodeling in rats with pressure overload-induced heart failure and related mechanisms. The objective was to provide a basis for the development of TIIA-related drugs for heart failure patients.

This study was carried out in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. The animal use protocol was approved by the Institutional Animal Care and Use Committee of Guizhou Provincial People’s Hospital.

In this study, the pressure overload induced-heart failure model of rats was successfully established by abdominal aorta constriction method, and the protective effect of TIIA on ventricular remodeling in this model was investigated. Results showed that, at the end of treatment, compared with model group, in TIIA group with certain dose the LVEF and LVFS were significantly increased, and the LVIDd and LVIDs were significantly decreased; the LVEDP was significantly decreased, and the LVSP, -d p /d tmax and +d p /d tma were significantly increased; the HWI and LVWI were significantly decreased. This suggests that TIIA can alleviate the ventricular remodeling in rats with pressure overload induced-heart failure. This is similar with a previous study 16 .

TIIA may alleviate ventricular remodeling in rats with pressure overload-induced heart failure heart by reducing inflammatory response and cardiomyocyte apoptosis.

 

Source:

http://doi.org/10.1590/s0102-865020190080000007

 

Leave a Reply

Your email address will not be published.